TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)

TriSalus Life Sciences, Inc.

Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).
Gross margin improved to ~90% in Q4 2023 and ~86% for FY2023, vs 75% and 82% a year ago.
Cash and equivalents $11.8M as of Dec 31, 2023; expects liquidity to fund operations into Q2 2024.
Revenue entirely from TriNav Infusion System; final audited financials not yet released.
Preliminary estimates are unaudited and subject to change; auditor has not performed any procedures.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TriSalus Life Sciences, Inc. reported fiscal year-ended December 31, 2023 results: revenue approximately $5.7 million for the fourth quarter of 2023.

Period: fiscal year-ended December 31, 2023
Revenue: approximately $5.7 million for the fourth quarter of 2023
Result: preliminary results

Exact text from the filing

On March 11, 2024, TriSalus Life Sciences, Inc. (the “Company”) announced a preliminary unaudited financial update with respect to the Company’s fiscal year-ended December 31, 2023.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-033157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.